You are here: Industry Insights > CyanVac

News List

CyanVac eyes fundraise for parainfluenza-vectored Covid-19 vaccine after December data Pharmaceutical-Technology
October 28, 2021
CyanVac expects its Phase I parainfluenza virus-vectored Covid-19 vaccine trial to have early data in December, which could be the impetus for a $30m fundraise.
CyanVac and Blue Lake Biotechnology Announce First Participant Dosed in a Phase 1 Clinical Trial to Evaluate its CVXGA1 Intranasal COVID-19 Vaccine prnewswire
September 28, 2021
CyanVac LLC and its subsidiary, Blue Lake Biotechnology, Inc., clinical-stage biopharmaceutical companies developing vaccines using a proprietary transformational parainfluenza virus 5 (PIV5)-based vector...
CyanVac and Exothera Enter COVID-19 Vaccine Partnership contractpharma
March 26, 2021
CDMO Exothera selected for the development and GMP manufacturing of intranasal vaccine candidate for Phase III clinical trial is Europe and the U.S.
CyanVac Selects Exothera for the Development and GMP Manufacturing of its COVID-19 Intranasal Vaccine Candidate for Phase III Clinical Trial is Europe and the US PharmaSources.com
March 25, 2021
CyanVac LLC, a vaccine company, announced that they have selected Exothera S.A., a full-service Contract Development and Manufacturing Organization (CDMO), for the development and manufacturing of their COVID-19 intranasal vaccine based on a ...